In addition, the activity of proTAME can be investigated in the context of other proteotoxic drug enhancers, such as the clinically approved HSP90-inhibitor pimitespib (TAS-116) or, because of the concerns that pimitespib (TAS-116) elevates the levels of PD-L1 on the surface of cells, the pre-clinical molecule tanespimycin, to determine whether any synergistic effect between the two occurs specifically in cancer cells [3,33]. This evidence concerns the gene CD274 and cancer.